Question follow-through · 87599

Lung Cancer: Screening

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential implications for his policies of the (a) level of rollout completion and (b) uptake rates of lung cancer screening programmes in each area where those s

answeredDepartment of Health and Social Care

About this written question

A written question asks a government minister for information in writing. Parliament publishes the question and any answer.

Answering body
Department of Health and Social Care
Tabled
3 Nov 2025
Target answer date
5 Nov 2025
Answer
10 Nov 2025 · 7 calendar days after tabling

Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.

More questions by this MP on Health and care

Shared topic keywords suggest a connection; they do not establish a follow-up.

Votes on this topic

These Commons divisions share a topic label. The question did not necessarily lead to a vote.

Recorded timeline

  1. 3 Nov 2025

    Question tabled

    To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential implications for his policies of the (a) level of rollout completion and (b) uptake rates of lung cancer screening programmes in each area where those s

  2. 5 Nov 2025

    Target answer date

    Date supplied by the official written-questions record.

  3. 10 Nov 2025

    Answer published

    The National Lung Cancer Screening Programme is designed to identify lung cancer at an earlier stage, particularly among people at highest risk. The programme offers screening to individuals aged 55 to 74 years old with a history of smoking, recognising t...

Open official record

Official data retrieved 28 Sept 2026.

Later records

Possible follow-up questions

Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Health: Offenders

27 Nov 2025 · To ask the Secretary of State for Health and Social Care, what the Department’s timelines are for implementing the recommendations set out in the Chief Medical Officer’s report, Health of People in Prison, on Probation and in the Secure NHS Estate in Engl

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Medical Treatments: Prisoners

27 Nov 2025 · To ask the Secretary of State for Health and Social Care, what specific actions the Department is taking, in response to the Chief Medical Officer’s report on the health of people in prison, published on 6 November 2025, to improve access to effective dru

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Continuing Care: Prisoners' Release

27 Nov 2025 · To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve continuity of care for people with drug treatment needs on release from prison, including ensuring effective links between prison and community drug t

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Mental Health Services: Rural Areas

8 Dec 2025 · To ask the Secretary of State for Health and Social Care, what steps he is taking to improve access to mental health services, particularly for young people and those in rural areas.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Mental Health Services: Men

8 Dec 2025 · To ask the Secretary of State for Health and Social Care, what steps his Department is taking to provide sustainable funding for grassroots men’s mental health initiatives.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Mental Health Services: Men

8 Dec 2025 · To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of volunteer-led men’s mental health groups on mental wellbeing and NHS services.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Prescriptions: Fees and Charges

2 Jan 2026 · To ask the Secretary of State for Health and Social Care, whether he plans to review the medical exemption list, in the context of their being no formal review since 1968.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Prescriptions: Fees and Charges

2 Jan 2026 · To ask the Secretary of State for Health and Social Care, what specific clinical, economic, or operational thresholds (e.g., prevalence shifts, new NICE guidance, excess out of pocket costs) would need to be met to trigger a formal review of the medical e

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Blood Cancer: Medical Treatments

13 Jan 2026 · To ask the Secretary of State for Health and Social Care, if he will take steps to ensure NHS patients with Mantle Cell Lymphoma will continue to be able to receive the CAR-T treatment Tecartus after it has exited the Cancer Drugs Fund.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Blood Cancer: Medical Treatments

13 Jan 2026 · To ask the Secretary of State for Health and Social Care, whether the forthcoming National Cancer Plan will contain measures to ensure patients with blood cancer can access lifesaving and cutting-edge new therapies via the NHS.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Epilepsy

10 Apr 2026 · To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the number of people in England with epilepsy who experience tonic-clonic seizures and are not seizure-free despite treatment.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Cancer: Clinical Trials

13 May 2026 · To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential implications for his policies of trends in the proportion of Phase II and Phrase III in commercial oncology clinical trials.